DekaBank Deutsche Girozentrale Purchases 2,535 Shares of IDEXX Laboratories, Inc. $IDXX

Key Points

• DekaBank Deutsche Girozentrale increased its stake in IDEXX Laboratories by 4.9%, acquiring an additional 2,535 shares in the second quarter, bringing its total to 54,792 shares worth approximately $29.2 million.
• Several hedge funds have significantly altered their positions in IDEXX Laboratories, with notable increases including Price T Rowe Associates raising its stake by 71.0% in the first quarter.
• IDEXX Laboratories recently reported $3.63 earnings per share for the quarter, exceeding analysts' expectations, and set its FY 2025 guidance at 12.400-12.760 EPS.

DekaBank Deutsche Girozentrale grew its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 4.9% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 54,792 shares of the company's stock after acquiring an additional 2,535 shares during the quarter. DekaBank Deutsche Girozentrale owned 0.07% of IDEXX Laboratories worth $29,228,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of IDXX. Price T Rowe Associates Inc. MD lifted its position in shares of IDEXX Laboratories by 71.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,988,912 shares of the company's stock worth $835,244,000 after acquiring an additional 825,965 shares during the period. Select Equity Group L.P. bought a new stake in shares of IDEXX Laboratories in the 1st quarter worth approximately $194,834,000. Nuveen LLC bought a new position in shares of IDEXX Laboratories during the 1st quarter worth approximately $179,784,000. Principal Financial Group Inc. lifted its position in shares of IDEXX Laboratories by 58.3% during the 1st quarter. Principal Financial Group Inc. now owns 1,126,002 shares of the company's stock worth $472,865,000 after buying an additional 414,802 shares during the period. Finally, Durable Capital Partners LP bought a new position in shares of IDEXX Laboratories during the 1st quarter worth approximately $153,180,000. Institutional investors own 87.84% of the company's stock.

Insider Transactions at IDEXX Laboratories

In other IDEXX Laboratories news, EVP Michael G. Erickson sold 406 shares of the company's stock in a transaction that occurred on Tuesday, August 12th. The stock was sold at an average price of $649.96, for a total value of $263,883.76. Following the sale, the executive vice president owned 11,287 shares in the company, valued at $7,336,098.52. This represents a 3.47% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Nimrata Hunt sold 1,200 shares of the company's stock in a transaction that occurred on Monday, August 11th. The shares were sold at an average price of $656.53, for a total value of $787,836.00. Following the completion of the transaction, the executive vice president directly owned 16,807 shares in the company, valued at $11,034,299.71. The trade was a 6.66% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 54,057 shares of company stock valued at $34,293,468. Company insiders own 0.98% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts recently commented on IDXX shares. Wall Street Zen downgraded IDEXX Laboratories from a "strong-buy" rating to a "buy" rating in a research report on Sunday, September 28th. Leerink Partners lifted their price objective on IDEXX Laboratories from $580.00 to $600.00 and gave the company an "outperform" rating in a research report on Thursday, July 17th. BTIG Research lifted their price objective on IDEXX Laboratories from $545.00 to $785.00 and gave the company a "buy" rating in a research report on Tuesday, August 5th. Jefferies Financial Group began coverage on IDEXX Laboratories in a research report on Tuesday, July 1st. They issued a "buy" rating and a $625.00 price objective for the company. Finally, JPMorgan Chase & Co. lifted their price objective on IDEXX Laboratories from $550.00 to $675.00 and gave the company an "overweight" rating in a research report on Monday, August 4th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, IDEXX Laboratories has an average rating of "Moderate Buy" and a consensus price target of $656.50.

IDEXX Laboratories Stock Performance

Shares of IDEXX Laboratories stock opened at $633.78 on Thursday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.11 and a quick ratio of 0.79. The firm has a market cap of $50.70 billion, a price-to-earnings ratio of 52.77, a price-to-earnings-growth ratio of 4.12 and a beta of 1.58. The stock's 50-day moving average is $638.91 and its 200-day moving average is $554.07. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $688.12.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The company reported $3.63 earnings per share for the quarter, topping the consensus estimate of $3.28 by $0.35. The company had revenue of $1.11 billion during the quarter, compared to analysts' expectations of $1.06 billion. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.IDEXX Laboratories's revenue for the quarter was up 10.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.44 earnings per share. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. Equities analysts predict that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.